ES2180702T3 - Tratamiento de patologias por la induccion del factor de transcripcion bef-1. - Google Patents

Tratamiento de patologias por la induccion del factor de transcripcion bef-1.

Info

Publication number
ES2180702T3
ES2180702T3 ES96303876T ES96303876T ES2180702T3 ES 2180702 T3 ES2180702 T3 ES 2180702T3 ES 96303876 T ES96303876 T ES 96303876T ES 96303876 T ES96303876 T ES 96303876T ES 2180702 T3 ES2180702 T3 ES 2180702T3
Authority
ES
Spain
Prior art keywords
bef
transcription factor
pathologies
induction
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96303876T
Other languages
English (en)
Inventor
David Thompson Berg
David Scott Calnek
Brian William Grinnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2180702T3 publication Critical patent/ES2180702T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

UN METODO PARA INDUCIR EL FACTOR DE TRANSCRIPCION BEF-1 QUE CONSISTE EN ADMINISTRAR A UNA PERSONA QUE LO NECESITE UNA CANTIDAD EFICAZ DE UN COMPUESTO CON LA FORMULA DONDE R{SUP,1} Y R{SUP,3} SON, INDEPENDIENTEMENTE, HIDROGENO, CH{SUB,3}, -C=O-(C{SUB,1}-C{SUB,6} ALQUIL) O -C=O-AR, DONDE AR ES UN FENILO OPCIONALMENTE SUSTITUIDO; R{SUP,2} SE SELECCIONA DE UN GRUPO FORMADO POR PIRROLIDINA, HEXAMETILENAMINO Y PIPERIDINO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ESTOS COMPUESTOS SOLVATADOS.
ES96303876T 1995-06-07 1996-05-30 Tratamiento de patologias por la induccion del factor de transcripcion bef-1. Expired - Lifetime ES2180702T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47949895A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ES2180702T3 true ES2180702T3 (es) 2003-02-16

Family

ID=23904277

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96303876T Expired - Lifetime ES2180702T3 (es) 1995-06-07 1996-05-30 Tratamiento de patologias por la induccion del factor de transcripcion bef-1.

Country Status (8)

Country Link
EP (1) EP0747051B1 (es)
JP (1) JPH11506771A (es)
AU (1) AU6040296A (es)
BR (1) BR9609053A (es)
CA (1) CA2223175A1 (es)
DE (1) DE69622472T2 (es)
ES (1) ES2180702T3 (es)
WO (1) WO1996040130A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
EP0963756B1 (en) * 1993-12-21 2004-02-25 Eli Lilly And Company Inhibition of advanced glycosylation end products
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin

Also Published As

Publication number Publication date
EP0747051A2 (en) 1996-12-11
BR9609053A (pt) 1999-01-26
WO1996040130A1 (en) 1996-12-19
AU6040296A (en) 1996-12-30
CA2223175A1 (en) 1996-12-19
JPH11506771A (ja) 1999-06-15
EP0747051B1 (en) 2002-07-24
DE69622472D1 (de) 2002-08-29
EP0747051A3 (en) 1997-02-26
DE69622472T2 (de) 2003-02-06

Similar Documents

Publication Publication Date Title
ES2180702T3 (es) Tratamiento de patologias por la induccion del factor de transcripcion bef-1.
ES2184850T3 (es) Peptidos y analogos peptidicos como inhibidores de proteasa.
ES2153851T3 (es) Tratamiento de la atrofia de la piel y de la vagina.
ES2102154T3 (es) Inhibicion de trombina.
ATE196140T1 (de) Substituierte benzylaminoquinuclidine als substanz p antagonisten
FI943542A0 (fi) Trisyklisiä bentsatsepiineja, jotka ovat vasopressiiniantagonisteja
ES2175336T3 (es) Derivados de triazol utiles en terapia.
EA200801805A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
NO20044458L (no) Anvendelse av en ringsystemforbindelse for fremstilling av et medikament
KR950010890A (ko) 폐경기 증후군의 치료방법
ES2122456T3 (es) Aminoacidos excitadores sinteticos.
ATE25682T1 (de) Indol-3-carboxamid-derivate.
DE69415507D1 (de) Analoge von acylfulven als antitumormittel
KR910016915A (ko) 과콜레스테롤혈증 치료제
KR880009953A (ko) 3-아미노-디하이드로-[1]-벤조피란 및 벤조티오피란
DE69431035D1 (de) 2-Phenyl-3-Azoylbenzothiophene zur Erhöhung der Thrombomodulin Expression
ES2195089T3 (es) Benzotiofenos amorfos, procedimientos de preparacion y uso.
SE9400810D0 (sv) New use of Quinoline-3-carboxamide compounds
ES2104509A1 (es) Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina.
ES2178382T3 (es) Compuestos de benciloxiprodigiosina.
ES2170804T3 (es) Derivados de dihidro-2,3-benzodiazepina.
DE59108026D1 (de) Phenylalkylaminoalkyl-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DK0404055T3 (da) Antimetastatisk virksomt stof fra den sydamerikanske igle Haementeria ghilianii
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.